Line by Line: Distinct Patterns of Anti-EGFR Antibody Resistance by Line of Therapy

The following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ryan B. Corcoran

Leadership: Alterome Therapeutics

Stock and Other Ownership Interests: Avidity Biosciences, nRichDx, C4 Therapeutics, Revolution Medicines, Kinnate Biopharma, Remix Therapeutics, Erasca, Inc, Alterome Therapeutics, Nested Therapeutics, Interline Therapeutics, Cogent Biosciences, Theonys

Consulting or Advisory Role: Taiho Pharmaceutical, N-of-One, FOGPharma, Array BioPharma, nRichDx, Elicio Therapeutics, C4 Therapeutics, Revolution Medicines, Natera, Kinnate Biopharma, Ipsen, AbbVie, Asana Biosciences, Remix Therapeutics

Research Funding: Lilly, Pfizer, Novartis

No other potential conflicts of interest were reported.